| Autor: |
Chen XH; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Lin HX; Department of Gastrointestinal Oncology Surgery, The Firsit Affiliated Hospital of Xiamen University, Xiamen 361000, China., Chen YH; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Wang XD; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Liu CQ; Department of Pathology,Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Huang HL; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Liang HY; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Zhang HM; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Li FP; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Liu H; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Hu YF; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., Li GX; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China., You J; Department of Gastrointestinal Oncology Surgery, The Firsit Affiliated Hospital of Xiamen University, Xiamen 361000, China., Zhao LY; Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Guangzhou 510515, China., Yu J; Department of General Surgery &, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. |
| Abstrakt: |
Objective: To investigate the effect of immune checkpoint inhibitors on reducing residual lymph node metastasis in patients with gastric cancer. Methods: The cohort of this retrospective study comprised patients from Nanfang Hospital of Southern Medical University and the First Affiliated Hospital of Xiamen University who had undergone systemic treatment prior to gastrectomy with D2 lymphadenectomy and had achieved Grade 1 primary tumor regression (TRG1) from January 2014 to December 2023. After exclusion of patients who had undergone preoperative radiotherapy, data of 58 patients (Nanfang Hospital: 46; First Affiliated Hospital of Xiamen University: 12) were analyzed. These patients were allocated to preoperative chemotherapy (Chemotherapy group, N =36 cases) and preoperative immunotherapy plus chemotherapy groups (Immunotherapy group, N =22 cases). There were no significant differences between these groups in sex, age, body mass index, diabetes, tumor location, pathological type, Lauren classification, tumor differentiation, pretreatment depth of invasion by primary tumor, pretreatment lymph node stage, pretreatment clinical stage, mismatch repair protein status, number of preoperative treatment cycles, or duration of preoperative treatment (all P >0.05). The primary outcome measure was postoperative lymph node downstaging. Secondary outcomes included postoperative depth of invasion by tumor, number of lymph nodes examined, and factors affecting residual lymph node metastasis status. Results: Lymph node downstaging was achieved significantly more often in the Immunotherapy group than the Chemotherapy group (pN0: 90.9% [20/22] vs. 61.1% [22/36]; pN1: 4.5% [1/22] vs. 36.1% [13/36]; pN2: 4.5% [1/22) vs. 0; pN3: 0 vs. 2.8% [1/36], Z =-2.315, P =0.021). There were no significant difference between the two groups in number of lymph nodes examined (40.5±16.3 vs. 40.8±17.5, t =0.076, P =0.940) or postoperative depth of invasion by primary tumor (pT1a: 50.0% [11/22] vs. 30.6% [11/36]; pT1b: 13.6% [3/22] vs. 19.4% [7/36]; pT2: 13.6% [3/22] vs. 13.9% [5/36]; pT3: 13.6% [3/22] vs. 25.0% [9/36]; pT4a: 9.1% [2/22] vs. 11.1% [4/36], Z =-1.331, P =0.183). Univariate analysis revealed that both preoperative treatment regimens were associated with residual lymph node metastasis status in patients whose primary tumor regression was TRG1 (χ 2 =6.070, P =0.014). Multivariate analysis incorporated the following factors: pretreatment depth of invasion by primary tumor, pretreatment lymph node stage, pretreatment clinical stage, number of preoperative treatment cycles, and preoperative treatment duration. We found that a combination of immunotherapy and chemotherapy administered preoperatively was an independent protective factor for reducing residual lymph node metastases in study patients whose primary tumor regression was TRG1 (OR=0.147, 95%CI: 0.026-0.828, P =0.030). Conclusion: Compared with preoperative chemotherapy alone, a combination of preoperative immunotherapy and chemotherapy achieved greater reduction of residual lymph node metastases in the study patients who achieved TRG1 tumor regression in their primary lesions. |
